Journal:

Article Title: A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent

doi: 10.1128/AAC.46.5.1447-1454.2002

Figure Lengend Snippet: MICs of CMT-3 and AMB

Article Snippet: The MIC of CMT-3 was 2.0 μg/ml, and the 50% inhibitory concentration was about 1.0 μg/ml. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Organism Source a MIC (μg/ml) of: No. of strains CMT-3 AMB C. albicans ATCC 24433, ATCC 76615, ATCC 18804, ATCC 90028, CI 0.25->8 0.12-4.0 17 C. albidus ATCC 34140 2.0 1.0 1 C. glabrata CI 4.0-8.0 0.5-2.0 2 C. krusei ATCC 6258, CI 4.0->8.0 1.0-2.0 3 C. parapsilosis ATCC 22019, CI >8.0 1.0-2.0 2 C. tropicalis ATCC 750, CI 4.0->8.0 0.5-2.0 3 Absidia sp. CI 4.0 4.0 1 A. flavus CI 2.0 1.0 1 A. fumigatus ATCC 1022 2.0 2.0 1 Cunninghamella sp. CI 8.0 >8.0 1 E. floccosum CI 0.5 >8.0 1 Fonsecaea sp. CI 4.0 >8.0 1 M. canis CI 2.0 0.5 1 M. gypseum CI 1.0 4.0 1 P. boydii CI 0.25 >8.0 1 Penicillium sp. CI 0.5 0.25 1 P. variotii ATCC 22319 1.0 0.5 1 P. verrucosa CI 8.0 >8.0 1 Rhizopus sp. CI 1.0 0.5 1 S. apiospermum CI 0.5 >8.0 1 T. mentagrophytes CI 1.0 4.0 1 T. tonsurans CI 2.0 0.25 1 Tricothecium sp. CI 0.5 >8.0 1 T. rubrum ATCC 10218 0.5 1.0 1 Ulocladium sp. CI 1.0 2.0 1 Open in a separate window a CI, clinical isolate.

Techniques:

Journal:

Article Title: A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent

doi: 10.1128/AAC.46.5.1447-1454.2002

Figure Lengend Snippet: Inhibition of fungal viability by CMT-3 and AMB

Article Snippet: The MIC of CMT-3 was 2.0 μg/ml, and the 50% inhibitory concentration was about 1.0 μg/ml. table ft1 table-wrap mode="anchored" t5 TABLE 2. caption a7 Organism Source a MIC (μg/ml) of: No. of strains CMT-3 AMB C. albicans ATCC 24433, ATCC 76615, ATCC 18804, ATCC 90028, CI 0.25->8 0.12-4.0 17 C. albidus ATCC 34140 2.0 1.0 1 C. glabrata CI 4.0-8.0 0.5-2.0 2 C. krusei ATCC 6258, CI 4.0->8.0 1.0-2.0 3 C. parapsilosis ATCC 22019, CI >8.0 1.0-2.0 2 C. tropicalis ATCC 750, CI 4.0->8.0 0.5-2.0 3 Absidia sp. CI 4.0 4.0 1 A. flavus CI 2.0 1.0 1 A. fumigatus ATCC 1022 2.0 2.0 1 Cunninghamella sp. CI 8.0 >8.0 1 E. floccosum CI 0.5 >8.0 1 Fonsecaea sp. CI 4.0 >8.0 1 M. canis CI 2.0 0.5 1 M. gypseum CI 1.0 4.0 1 P. boydii CI 0.25 >8.0 1 Penicillium sp. CI 0.5 0.25 1 P. variotii ATCC 22319 1.0 0.5 1 P. verrucosa CI 8.0 >8.0 1 Rhizopus sp. CI 1.0 0.5 1 S. apiospermum CI 0.5 >8.0 1 T. mentagrophytes CI 1.0 4.0 1 T. tonsurans CI 2.0 0.25 1 Tricothecium sp. CI 0.5 >8.0 1 T. rubrum ATCC 10218 0.5 1.0 1 Ulocladium sp. CI 1.0 2.0 1 Open in a separate window a CI, clinical isolate.

Techniques: Inhibition, Control

Journal: Brazilian Journal of Microbiology

Article Title: A fluorometric hybridization assay for detecting and genotyping high-risk human papillomavirus 16 and 18 in archival tissues of cervical specimens

doi: 10.1007/s42770-019-00137-8

Figure Lengend Snippet: HPV types 16 and 18 prevalence in patients with different types of cervical dysplasia

Article Snippet: Source of plasmids DNA DNA plasmids containing the entire genomes of HPV16 (ATCC 45113D) and HPV18 (ATCC 45152D) were purchased from American Type Culture Collection (ATCC, Manassas, USA) and used as the control to develop efficient hybridization methods.

Techniques:

Journal: Brazilian Journal of Microbiology

Article Title: A fluorometric hybridization assay for detecting and genotyping high-risk human papillomavirus 16 and 18 in archival tissues of cervical specimens

doi: 10.1007/s42770-019-00137-8

Figure Lengend Snippet: HPV types 16 and 18 overall detection via three different methods

Article Snippet: Source of plasmids DNA DNA plasmids containing the entire genomes of HPV16 (ATCC 45113D) and HPV18 (ATCC 45152D) were purchased from American Type Culture Collection (ATCC, Manassas, USA) and used as the control to develop efficient hybridization methods.

Techniques:

Journal: Brazilian Journal of Microbiology

Article Title: A fluorometric hybridization assay for detecting and genotyping high-risk human papillomavirus 16 and 18 in archival tissues of cervical specimens

doi: 10.1007/s42770-019-00137-8

Figure Lengend Snippet: Comparison between the results obtained for the identification of HPV 16 and 18, with TSnPCR and with MCHA

Article Snippet: Source of plasmids DNA DNA plasmids containing the entire genomes of HPV16 (ATCC 45113D) and HPV18 (ATCC 45152D) were purchased from American Type Culture Collection (ATCC, Manassas, USA) and used as the control to develop efficient hybridization methods.

Techniques: Comparison

Journal: Brazilian Journal of Microbiology

Article Title: A fluorometric hybridization assay for detecting and genotyping high-risk human papillomavirus 16 and 18 in archival tissues of cervical specimens

doi: 10.1007/s42770-019-00137-8

Figure Lengend Snippet: Comparison of the results obtained for the identification of HPV 16 and 18, with TSnPCR and with MFHA

Article Snippet: Source of plasmids DNA DNA plasmids containing the entire genomes of HPV16 (ATCC 45113D) and HPV18 (ATCC 45152D) were purchased from American Type Culture Collection (ATCC, Manassas, USA) and used as the control to develop efficient hybridization methods.

Techniques: Comparison

Journal: Journal of Biological Chemistry

Article Title: Phosphorylation of p50 NF-κB at a Single Serine Residue by DNA-dependent Protein Kinase Is Critical for VCAM-1 Expression upon TNF Treatment

doi: 10.1074/jbc.m110.158352

Figure Lengend Snippet: FIGURE 1. DNA-PK is required for VCAM-1 expression in response to TNF treatment. A, immunoblot analysis of extracts from untreated M059K (DNA- PK-proficient) or M059J (DNA-PK-deficient) cells with antibodies to human DNA-PKcs or GAPDH. B, M059K and M059J cells were stimulated with TNF for different times, after which protein extracts were subjected to immunoblot analysis with antibodies to VCAM-1 or GAPDH. Con, control. C, M059K and M059J cells were stimulated with 2 or 10 ng/ml IL-1 for 18 h, after which protein extracts were subjected to immunoblot analysis with antibodies to VCAM-1 or GAPDH. D and E, cells were treated with TNF for 6 h, after which total RNA was prepared and subjected to cDNA generation followed by conven- tional (D) or quantitative (E) PCR with primers specific to human VCAM-1 or -actin. *, different from respective untreated cells; #, different from TNF-treated M059K cells; p 0.01. F, M059K cells were treated with different doses of DNA-PKcs siRNA; 48 h later, protein extracts were prepared and subjected to im- munoblot analysis with antibodies to DNA-PKcs or GAPDH. G, M059K cells were treated with siRNA against DNA-PKcs or control siRNA; 48 h later, cells were treated with TNF for 18 h. Protein extracts were subjected to immunoblot analysis with antibodies to VCAM-1 or GAPDH. H, M059K cells were transduced with a lentiviral vector (Santa Cruz Biotechnology) expressing either control shRNA or an shRNA targeting DNA-PKcs. Forty-eight hours later, cells were treated with TNF for 18 h, and the resulting protein extracts were subjected to immunoblot analysis with antibodies to DNA-PKcs, VCAM-1, or GAPDH.

Article Snippet: H, M059K cells were transduced with a lentiviral vector (Santa Cruz Biotechnology) expressing either control shRNA or an shRNA targeting DNA-PKcs.

Techniques: Expressing, Western Blot, Control, Transduction, Plasmid Preparation, shRNA

Journal:

Article Title: Potato Dextrose Agar Antifungal Susceptibility Testing for Yeasts and Molds: Evaluation of Phosphate Effect on Antifungal Activity of CMT-3

doi: 10.1128/AAC.46.5.1455-1461.2002

Figure Lengend Snippet: Comparison of the MICs of fluconazole, ketoconazole, and CMT-3 determined by the BMM and the PDA method

Article Snippet: For these two azole drugs, the BMM/PDA method MIC ratios were between 0.25 and 1 (no more than a 2 log 2 dilution difference), values which represent an allowable shift in laboratory practice. table ft1 table-wrap mode="anchored" t5 TABLE 4. caption a7 Organism a and antifungal agent MIC (μg/ml) determined by: Difference b (log 2 dilutions) BMM PDA method C. parapsilosis (ATCC 22019) Fluconazole 2.0 4.0 +1 Ketoconazole 0.12 0.12 0 C. krusei (ATCC 6258) Fluconazole 32 32 0 Ketoconazole 0.5 1.0 +1 P. boydii (CI) Fluconazole 8 16 +1 Ketoconazole 1.0 2.0 +1 CMT-3 32 0.25 −7 C. glabrata (CI) Fluconazole 8 16 +1 Ketoconazole 4.0 4.0 0 CMT-3 32 4 −3 Y. lipolytica (CI) Fluconazole 2.0 4.0 +1 Ketoconazole 0.25 1.0 +2 CMT-3 32 2.0 −4 C. albicans (ATCC 24433) Fluconazole 4.0 4.0 0 CMT-3 16 0.5 −5 P. variotii (ATCC 22319) Ketoconazole 0.12 0.25 +1 CMT-3 16 1.0 −4 A. fumigatus (ATCC 1022) Ketoconazole 4.0 4.0 0 CMT-3 >64 2.0 <−5 Penicillium sp. (CI) Ketoconazole 1.0 2.0 +1 CMT-3 16 0.5 −5 Rhizopus sp. (CI) Ketoconazole 1.0 4.0 +2 CMT-3 32 1.0 −5 A. flavus (CI), CMT-3 64 2.0 −5 Open in a separate window a CI, clinical isolate. b Difference between PDA method result and BMM result.

Techniques: Comparison